Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying
The stock is known to soar on good news.
Overview
Viking Therapeutics (NASDAQ: VKTX) is one of the hopefuls in a very exciting pharmaceutical and biotech space right now: the weight loss drug market. Today, pharma giants Eli Lilly and Novo Nordisk dominate this area with their drugs, but demand is so high that there is room for a newcomer or newcomers to carve out a share -- and generate growth. This market is expected to reach almost $100 billion in just a few years, and demand for the products remains high.
Viking develops potential drugs for endocrine and metabolic disorders, and its lead candidate VK2735 is involved in late-stage trials for the weight loss indication. This biotech has reached a key moment in its growth story, suggesting stock price performance in the months and quarters ahead. Is Viking stock going to $50? Let's check out what the bulls and the bears are saying.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.